News: Portfolio 2009

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director; Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

(continued)

Top Line Study Results

Logical also announced the reporting of data from its double-blind, randomized, active comparator study of LT-NS001 vs. naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen.

 

In the study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen. The full results from this study will be presented at scientific meeting during the third quarter of 2009. See below for additional information on LT-NS001.

 

quarter of 2009. See below for additional information on LT-NS001.

 

Financing Milestone Achieved

As a result of completing this proof-of-concept study demonstrating the improved GI safety of LT-NS001 in humans, Logical Therapeutics' has successfully completed all of the milestones associated with its Series B financing round. Logical intends to continue to progress the clinical development of LT-NS001, as well as its other programs, to fully explore their commercial potential as candidates for partnering.

 

About LT-NS001

LT-NS001 is a novel, patented NCE pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed by Logical Therapeutics to significantly decrease the GI safety risks associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

 

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and

Page: 1 234